1. HOME
2. Research Insight
3. F. Hoffmann-La Roche Ltd (Switzerland) and Merck KGaA (Germany) are Leading players in the Biomarkers Market

The biomarkers market is expected to reach USD 93.8 billion in 2029 from USD 57.7 billion in 2024, at a CAGR of 10.2% during the forecast period. The major factors driving the growth of this market include the growing importance of companion diagnostics, the increase in the global prevalence of cancer, and the growing importance of biomarkers for rare conditions.

The global biomarkers market is fragmented with top players such as F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), and QIAGEN (Germany). The market players have adopted various strategies such as new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions to strengthen their position in the global biomarkers market.

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd (Switzerland)

F. Hoffmann-La Roche Ltd is a research-based global healthcare company with expertise in diagnostics and pharmaceuticals. The company develops and manufactures innovative medicines, diagnostic instruments, and tests. The company mainly operates in the US, the UK, Switzerland, Oceania, Japan, Germany, Spain, France, Austria, Brazil, and Belgium, among other countries. Roche offers a wide range of products and services in the biomarkers market. This includes a comprehensive portfolio of diagnostic tests and technologies for detecting and measuring biomarkers associated with various diseases such as cancer, infectious diseases, cardiovascular disorders, and more. Their assays and tests aid in the early detection, monitoring, and treatment selection of patients. Additionally, the company continues to develop and manufacture innovative products. For instance, in February 2023, F. Hoffmann-La Roche Ltd launched two new antibodies to understand a patient's brain tumor mutation status in the IDH1 and ATRX genes that help in more informed clinical decisions and may improve patient outcomes.

Merck KGaA (Germany)

Merck KGaA is a healthcare & life sciences company that develops, manufactures, and markets pharmaceutical and biopharmaceutical products, specialty chemicals, high-tech materials, and life science research and diagnostic tools. The company offers various biomarkers products, including reagents, kits, assays, and software, catering to various research, bioprocessing, and clinical applications. The company has a strong international presence, with a wide distribution network and established relationships with research institutions, biotech, and pharmaceutical companies worldwide. Additionally, the company has strategically expanded its global footprint by developing collaborations and partnerships. For instance, in January 2024, Quibim and Merck KGaA partnered to develop diagnostic tools to build the next generation of precision medicine technology targeting a wide range of cancers.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is one of the leading players in the life science industry. The company develops, manufactures, sells, and distributes analytical instruments, equipment, reagents & consumables, software, and services. The company is known for its premier brands, such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. With a global presence and a reputation for high-quality products and innovative technologies, Thermo Fisher Scientific is a trusted partner for laboratories, research institutions, and pharmaceutical companies involved in biomarker research. Their commitment to advancing scientific research and improving patient outcomes makes them a key player in the biomarkers market. The company operates in over 180 countries across North America, Europe, Asia, the Middle East, Africa, and Latin America. Further, the company continues to invest in research and development to offer innovative and a broad range of products. For instance, in 2023, the company invested USD 1.34 billion in research and development.

Related Reports:

Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]